Posted by Michael Wonder on 06 Nov 2024
Expanded age indication for GSK's Arexvy, the first respiratory syncytial virus vaccine approved in Canada for adults aged 50-59 at increased risk
5 November 2024 - Clinical development program continues to evaluate safety and immunogenicity in adults aged 18-49 at increased risk of respiratory syncytial virus disease and immunocompromised adults aged 18 and over (authorization in these populations has not yet been granted).
GSK's Arexvy (respiratory syncytial virus vaccine - recombinant, AS01E adjuvanted) has been approved in Canada for the prevention of lower respiratory tract disease caused by respiratory syncytial virus in adults 50-59 years of age who are at increased risk for respiratory syncytial virus disease.
